帕肝素钠(Parnaparin Sodium) - 药物靶点：factor Xa_在研适应症：血栓形成，溃疡性结肠炎_专利_临床

Prospective randomized study of patients with infertility candidates to Assisted ReproductiveTechniques (ART), screened for all inclusion and exclusion criteria, submitted to ART cycle with or without low molecular weight heparin (LMWH) administration. Aims of the study are to evaluate, primarily, pregnancy rate/embryo transfer, secondarily take home babies/embryo transfer, implantation rate, and the role of thrombophilic factors

开始日期2011-07-01

申办/合作机构

Humanitas SpA

NCT00732927 / Terminated临床3期

Parnaparin Versus Aspirin in the Treatment of Retinal Vein Occlusion. A Randomized, Double Blind, Controlled Study

Retinal vein occlusion (RVO) is the second commonest retinal disease after diabetic retinopathy, and is a common cause of unilateral visual loss. There are two aims in the management of RVO: the identification of modifiable risk factors and their medical management and the recognition and management of sight-threatening complications. The management of the disease includes laser therapy and the control of systemic associated diseases. Many other treatments have been proposed but there is no evidence on their efficacy in modulating the outcome of branch or central RVO. There are currently no adequate clinical trials that have evaluated the efficacy and safety of antithrombotic agents in this setting. Antiplatelet agents are frequently used in clinical practice. Anticoagulant drugs, either heparins or coumarins, are also used in this setting as they represent the first line therapy for the treatment of venous thromboembolism. Aim of this randomized controlled study is to to compare the efficacy and safety of aspirin and of a low molecular weight heparin, parnaparin, in the treatment of RVO. Study treatment is administered for 3 months. Primary end-point of the study is the incidence of functional worsening of the eye with RVO at 6 months. Secondary efficacy outcomes are the following: proportion of cases requiring laser treatment because of the extension of the ischemic lesion and/or the presence of neovascularisation and/or macular oedema, incidence of recurrent RVO objectively documented by fluorescein angiography. Safety outcomes are defined by the incidence of major and minor bleeding events.

开始日期2002-07-01

申办/合作机构

University of Insubria

[+1]

100 项与帕肝素钠相关的临床结果

登录后查看更多信息

100 项与帕肝素钠相关的转化医学

登录后查看更多信息

100 项与帕肝素钠相关的专利（医药）

登录后查看更多信息

60

项与帕肝素钠相关的文献（医药）

2023-01-01·SAGE Open Medical Case Reports

Primary thromboprophylaxis in not surgically treated intra-luminal gastrointestinal cancer (ILGC) treated with first-line chemotherapy: A single institution preliminary safety report

作者: Dottore, Alessia ; Giaimo, Valentina ; D’Angelo, Alessandro ; D’Amore, Fabio ; Colina, Paolo ; Vitale, Felice V ; Raffaele, Mario

Occurrence of venous thromboembolism in cancer patients (patients) undergoing chemotherapy is a remarkable concern for the oncologist. In addition, careful attention has to be paid to the possible major bleeding when patients carrying gastrointestinal cancer need antithrombotic therapies. To date some Cancer Associated Thrombosis (CAT) risk scores as Khorana and PROTECHT score have been developed to identify the cancer population at high-risk for venous thromboembolism (VTE). Consensus guidelines recommend to consider also low molecular weight heparin (LMWH) for primary thromboprophylaxis in high-risk patients. This is a report on a retrospective case series of 15 intra-luminal not surgically treated gastrointestinal cancer patients deemed high risk for VTE. The patients had a Khorana or PROTECHT score of 2 points or more (at least ≥ 2 points). They were undergoing first line chemotherapy in the absence of endoscopic signs of cancer spontaneous bleeding. A prophylactic dose of LMWH was administered just before starting the chemotherapy session and until 48 hours after its completion. The authors mainly aimed to report occurrence of clinically perceptible gastrointestinal bleeding events. Fifteen patients were administered LMWH – median age: 59 (range: 42–79); gender: male 12 (80%); tumor type: stomach – 13 patients (86%); gastro-esophageal junction: 2 patients (14%). Duration of heparin treatment: the total treatment duration was 228 days; mean 15.2 days (range: 5–45); nadroparin: mean 14.7 days (range: 5–45); enoxaparin: mean 10.1 days (range: 5–20); parnaparin: a total of 5 days. None of the patients experienced perceptible gastrointestinal bleeding. Short-term LMWH thromboprophylaxis appeared to be safe for this series of patients.

2020-01-01·Khirurgiya. Zhurnal im. N.I. Pirogova

The use of parnaparin sodium (Fluxum) in the prevention of thromboembolic complications after surgical treatment of fractures associated with high risks of thrombosis

Article

作者: Kaplunov, K O ; Kaplunov, O A

The need for thromboprophylaxis in traumatological and orthopedic operations is determined by a constant increase in the level of injuries of the population, and as a result, fluctuating coagulation indicators. Risk factors inherent in modern society that correlate primarily with reduced physical activity and excessive consumption of unbalanced (carbohydrate) nutrition, bad habits (nicotinism, alcoholism and other toxic dependencies), increased life expectancy and comorbidity - these and other causes can lead to an increase in the incidence of vascular accidents in patients with large limb bone fractures. The goal is to compare the effectiveness and clinical safety of using parnaparin sodium (Fluxum) and enoxaparin sodium as the prevention of thrombosis in the treatment of lower limb bone fractures.MATERIAL AND METHODSA comparative assessment of the effectiveness and clinical safety of thrombosis prevention in the treatment of lower limb bone fractures using low-molecular weight heparins: parnaparin sodium (Fluxum) and enoxaparin sodium.RESULTSTaking into account the literature data on the significant risk of venous thromboembolic complications, we successfully conduct the thromboprophylaxis in patients with the traumatological and orthopedic profile, including in 2019 using the drug parnaparin sodium (Fluxum, «Alfasigma»). Our own comparative clinical experience has shown that with the convenience of taking enoxaparin sodium and the completeness of the scheme, the prevention of thrombosis with the use of parnaparin sodium shows the tendency to better clinical effectiveness and safety.CONCLUSIONThe choice of anticoagulants in traumatological and orthopedic practice, with obvious ease of use, provides the complete scheme for the prevention of thrombosis. Further research is needed on the routine use of sodium parnaparin in order to prevent thronbosis in the treatment of fractures of various localization.

2020-01-01·Khirurgiya. Zhurnal im. N.I. Pirogova

Parnaparin sodium — modern therapy options and prevention of venous thromboembolic complications

Article

作者: Petrikov, A S

Venous thromboembolic complications (VTEC) including pulmonary embolism and acute thrombosis of deep and superficial veins of the lower extremities are often observed in postoperative period. Low-molecular-weight heparin (LMWH) is a common remedy for prevention and treatment of VTEC due to high efficiency, safety, easy use and dosage. According to the modern literature data, LMWH is characterized by different effectiveness in relation to VTEC and risk of bleeding in patients after surgical and traumatological procedures, as well as in ones with severe forms of chronic venous diseases. However, their antithrombin activity varies significantly depending on mean molecular weight. The authors analyze LMWH action mechanism, pharmacokinetic and pharmacodynamic features of LMWH, in particular parnaparin sodium. Efficacy, safety and tolerability of this remedy for various forms of VTEC (superficial and deep vein thrombosis, thrombophlebitis, complicated forms of chronic venous diseases), its advantages for prevention of VTEC after various surgical and orthopedic interventions are considered.

100 项与帕肝素钠相关的药物交易

登录后查看更多信息